Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-wide life science investor/ venture capital firm.
Novo Holding's mission is to be a supportive owner of the Novo Group companies and to make a growing impact on health, science, and society by generating long-term returns on the assets of the Novo Nordisk Foundation.
Novo Holdings employs investment and business professionals focused on delivering attractive returns for the benefit of the Novo Nordisk Foundation.
Timeline
June 15, 2021
Novo Holdings announces that it has acquired BBI Group ("BBI") from Exponent for an enterprise value of over GBP 400 million.
Funded Companies
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
FinSMEs
July 27, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Brandon May
July 9, 2021
BioSpace
The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases.
FinSMEs
July 9, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
FinSMEs
June 25, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Novo Holdings
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Holdings A/S, a leading global life sciences investor, today announced it has acquired BBI Group ("BBI"), a leading supplier of products...
Novo Holdings
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Holdings today announced that it has co-led with Vivo Capital the over-subscribed US$200 million Series A and Crossover round in Esco...
Nick Paul
May 26, 2021
FierceBiotech
Esco Lifesciences has raised $200 million in a series A and crossover round co-led by Novo Holdings and Vivo Capital. The Singapore-based company will use the cash to establish a hub for cell and gene therapy tools and technologies in Boston while expanding in China and making bolt-on acquisitions.
Novo Holdings
May 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab...
Kyle LaHucik
May 18, 2021
FierceBiotech
Hummingbird Bioscience can chirp a little louder this morning with an oversubscribed $125 million series C led by Novo Holdings, the investment arm of Novo Nordisk. The Hummingbird financing signals one of the first investments in a privately held Asian biotech by the Danish pharma company.
Novo Holdings
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an...
FinSMEs
May 11, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Novo Holdings
May 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Growth, the growth equity arm of Novo Holdings, today announced that it has led a EUR 29 million series C investment in AMSilk, the...
Ben Adams
May 6, 2021
FierceBiotech
Altasciences, just weeks after it was bought out by Novo Holdings, is remaining bullish on its buyout as it grabs Calvert Laboratories.
Ben Adams
February 23, 2021
FierceBiotech
Hot on the heels of a deal that saw Canadian CRO Altasciences buy out WCCT Global, the company was then acquired itself by Novo Holdings.
Novo Holdings
February 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Holdings A/S, a world-leading life science investor with a focus on long-term, sustainable value creation, today announced that it has...
Novo Holdings
January 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- Key Numbers $570 million invested in the life sciences 39 public investments including 9 portfolio company IPOs 33 venture financings including...
Novo Holdings
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Novo Ventures, the ventures arm of Novo Holdings, today announces its participation in the BioGeneration Ventures (BGV) oversubscribed fourth...
Novo Holdings
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company...
Novo Holdings
December 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that it has invested in a new portfolio...
Maija Palmer
December 8, 2020
Sifted
It is bigger than the Gates Foundation by assets, and will feature in virtually every biotech company's cap table at some stage.
SHOW MORE
References
Venture capital firmVenture Capital Firm attributes
Location
Gentofte Municipality
MycoWorks
iRhythm Technologies
Biosyntia
Verona Pharma
Tempus Labs (company)
Kebotix
StrideBio
LanzaTechFounded date
September 8, 1999
Other attributes
Novo Nordisk
NNIT
Chr. Hansen
Novozymes
FLSmidth
NMD PharmaCountry
DenmarkLegal classification
AktieselskabParent organization
Novo Nordisk FoundationSubsidiary
Wikidata ID
